Carmaker Daimler targets doubling last year's record 12,000 unit sales of its luxury Mercedes-Maybach vehicles, helped by strong demand in China.
The Maybach, which costs between $173,000 to over $250,000, are used widely as limousines in China, the car's biggest market.
According to its CEO Ola Kaellenius, the sales growth rate for the Maybach in China was in double figures while Russia, South Korea, and the US have shown strong demand.
The new Maybach model, based on a Mercedes-Benz S-Class, is designed for chauffeured trips and will compete with the likes of the Rolls-Royce Ghost and the Bentley Flying Spur.
The car may be acquired with optional extras like silver champagne flutes, massaging calf rests, and automated rear doors.
Daimler, which unveiled the latest version of its $200,000 Mercedes-Maybach S-Class sedan, is focusing more on large luxury vehicles like the S-Class as part of its strategy to improve profits.
Daimler also plans to make a range of fully electric Maybach models, which are likely to do well in China.
China is switching to electric vehicles (EV) and wants new energy vehicle (NEV) sales to reach around a quarter of all car sales in 2025, prompting carmakers to revise its EV targets.
China plans to be carbon neutral by 2060.


Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Instagram Outage Disrupts Thousands of U.S. Users
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 



